What type of study is this?

September 30, 2025

Figure 2 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer

Key Points

Progression-free survival (PFS) was assessed in patients treated with binimetinib and palbociclib.
Kaplan-Meier curves and swimmer plots revealed treatment effects in a cohort of 23 patients with advanced breast cancer.
A waterfall plot demonstrated the best overall response among 16 patients with measurable disease.
Mutational status analysis highlighted key gene mutations associated with the efficacy of the treatment.

Abstract

Efficacy results. A, Kaplan–Meier (KM) curve and (B) swimmer plot displaying PFS time for the efficacy population (N = 23). C, Waterfall plot showing the best overall response for the 16 patients with measurable disease. The mutational status of the most frequently mutated genes in TNBC is shown underneath the waterfall plot. D, Spider plot of the efficacy population.

Figure 2 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer

Key Points

Abstract

Cite This Study